Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].

Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, Guibert N, Melloni B, Raherisson C, Didier A, Mazieres J.

Rev Mal Respir. 2019 Jun 12. pii: S0761-8425(19)30136-6. doi: 10.1016/j.rmr.2019.04.003. [Epub ahead of print] French.

PMID:
31202602
2.

Genomic characterization of metastatic breast cancers.

Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, Soria JC, Dien AT, Adnani Y, Kamal M, Garnier S, Meurice G, Jimenez M, Dogan S, Verret B, Chaffanet M, Bachelot T, Campone M, Lefeuvre C, Bonnefoi H, Dalenc F, Jacquet A, De Filippo MR, Babbar N, Birnbaum D, Filleron T, Le Tourneau C, André F.

Nature. 2019 May;569(7757):560-564. doi: 10.1038/s41586-019-1056-z. Epub 2019 May 22.

PMID:
31118521
3.

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B.

Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.

4.

Gated FDG/CT of the lung using a spirometric respiratory gating device : a feasibility study.

Jaudet C, Filleron T, Weyts K, Didierlaurent D, Vallot D, Ouali M, Zerdoud S, Dierickx OL, Caselles O, Courbon F.

J Nucl Med Technol. 2019 Apr 24. pii: jnmt.118.223339. doi: 10.2967/jnmt.118.223339. [Epub ahead of print]

PMID:
31019044
5.

Éditorial.

Andrieu S, Filleron T; Comités scientifique et d’organisation.

Rev Epidemiol Sante Publique. 2019 May;67 Suppl 3:S119. doi: 10.1016/j.respe.2019.03.001. Epub 2019 Apr 5. French. No abstract available.

PMID:
30955996
6.

The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer.

Esteyrie V, Gleyzolle B, Lusque A, Graff P, Modesto A, Rives M, Lapeyre M, Desrousseaux J, Graulières E, Hangard G, Arnaud FX, Ferrand R, Delord JP, Poublanc M, Mounier M, Filleron T, Laprie A.

Clin Transl Radiat Oncol. 2019 Mar 9;16:34-39. doi: 10.1016/j.ctro.2019.02.006. eCollection 2019 May.

7.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Laprie A, Ken S, Filleron T, Lubrano V, Vieillevigne L, Tensaouti F, Catalaa I, Boetto S, Khalifa J, Attal J, Peyraga G, Gomez-Roca C, Uro-Coste E, Noel G, Truc G, Sunyach MP, Magné N, Charissoux M, Supiot S, Bernier V, Mounier M, Poublanc M, Fabre A, Delord JP, Cohen-Jonathan Moyal E.

BMC Cancer. 2019 Feb 21;19(1):167. doi: 10.1186/s12885-019-5317-x.

8.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Feb 20. doi: 10.1002/cpt.1404. [Epub ahead of print]

PMID:
30786012
9.

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, de La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F.

Ann Surg Oncol. 2019 Feb;26(2):356-365. doi: 10.1245/s10434-018-6831-9. Epub 2018 Dec 11.

PMID:
30539492
10.

Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.

Garandeau D, Noujarède J, Leclerc J, Imbert C, Garcia V, Bats ML, Rambow F, Gilhodes J, Filleron T, Meyer N, Brayer S, Arcucci S, Tartare-Deckert S, Ségui B, Marine JC, Levade T, Bertolotto C, Andrieu-Abadie N.

Mol Cancer Ther. 2019 Feb;18(2):289-300. doi: 10.1158/1535-7163.MCT-17-1141. Epub 2018 Nov 27.

PMID:
30482853
11.

Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model.

Brun T, Ferron G, Filleron T, Bonnet J, Martinez A, Ducassou A, Corbiere F, Delannes M.

J Contemp Brachytherapy. 2018 Oct;10(5):463-469. doi: 10.5114/jcb.2018.79470. Epub 2018 Oct 31.

12.

Prospective evaluation of the performances of narrow-band imaging flexible videoscopy relative to white-light imaging flexible videoscopy, in patients scheduled for transurethral resection of a primary NMIBC.

Dalgaard LP, Zare R, Gaya JM, Redorta JP, Roumiguié M, Filleron T, Malavaud B.

World J Urol. 2018 Oct 26. doi: 10.1007/s00345-018-2537-7. [Epub ahead of print]

PMID:
30367204
13.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.

Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569.

PMID:
30299429
14.

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.

Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Da Mota DF, Gilhodes J, Filleron T, Siegfried A, Evrard S, Kowalski-Chauvel A, Moyal EC, Toulas C, Lemarié A.

Mol Cancer Res. 2019 Feb;17(2):384-397. doi: 10.1158/1541-7786.MCR-18-0386. Epub 2018 Sep 28.

PMID:
30266751
15.

Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.

Cabarrou B, Sfumato P, Mourey L, Leconte E, Balardy L, Martinez A, Delord JP, Boher JM, Brain E, Filleron T.

Eur J Cancer. 2018 Nov;103:120-126. doi: 10.1016/j.ejca.2018.07.136. Epub 2018 Sep 14.

PMID:
30223225
16.

Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?

Gaspard M, Lamant L, Tournier E, Valentin T, Rochaix P, Terrier P, Ranchere-Vince D, Coindre JM, Filleron T, Le Guellec S.

Histopathology. 2018 Dec;73(6):969-982. doi: 10.1111/his.13740. Epub 2018 Oct 23.

PMID:
30137667
17.

Focus on an infrequently used quantity in the context of competing risks: The conditional probability function.

Cabarrou B, Dalenc F, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2018 Oct 1;101:70-81. doi: 10.1016/j.compbiomed.2018.08.002. Epub 2018 Aug 4.

PMID:
30103091
18.

Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.

Cabarrou B, Sfumato P, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2018 Sep 1;100:239-246. doi: 10.1016/j.compbiomed.2018.06.034. Epub 2018 Jun 30.

PMID:
30055524
19.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

PMID:
30017832
20.

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B.

Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5.

PMID:
29973670
21.

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25154. [Epub ahead of print]

22.

Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.

Le Guellec S, Lesluyes T, Sarot E, Valle C, Filleron T, Rochaix P, Valentin T, Pérot G, Coindre JM, Chibon F.

Ann Oncol. 2018 Aug 1;29(8):1828-1835. doi: 10.1093/annonc/mdy194.

PMID:
29860427
23.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H.

BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.

24.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.

Longué M, Cabarrou B, Wallet J, Brodowicz T, Roché H, Boher JM, Delord JP, Penel N, Filleron T.

Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.

PMID:
29722789
25.

Alternative methodological approach to randomized trial for surgical procedures routinely used.

Filleron T, Lusque A, Dalenc F, Ferron G, Roche H, Martinez A, Jouve E.

Contemp Clin Trials. 2018 May;68:109-115. doi: 10.1016/j.cct.2018.03.016. Epub 2018 Mar 30.

PMID:
29608972
26.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

27.

New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.

Brun T, Bachaud JM, Graff-Cailleaud P, Malavaud B, Portalez D, Popotte C, Aziza R, Lusque A, Filleron T, Ken S.

Brachytherapy. 2018 May - Jun;17(3):544-555. doi: 10.1016/j.brachy.2018.01.011. Epub 2018 Mar 7.

PMID:
29525514
28.

IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.

Graff P, Portalez D, Lusque A, Brun T, Aziza R, Khalifa J, Roumiguié M, Quintyn Ranty ML, Filleron T, Bachaud JM, Malavaud B.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):903-911. doi: 10.1016/j.ijrobp.2018.01.066. Epub 2018 Feb 2.

PMID:
29510957
29.

Total body irradiation using Helical Tomotherapy®: Treatment technique, dosimetric results and initial clinical experience.

Sarradin V, Simon L, Huynh A, Gilhodes J, Filleron T, Izar F.

Cancer Radiother. 2018 Feb;22(1):17-24. doi: 10.1016/j.canrad.2017.06.014.

PMID:
29395854
30.

Comparing sensitivity and specificity of medical imaging tests when verification bias is present: The concept of relative diagnostic accuracy.

Filleron T.

Eur J Radiol. 2018 Jan;98:32-35. doi: 10.1016/j.ejrad.2017.10.022. Epub 2017 Oct 31. Review.

PMID:
29279167
31.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.

Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

32.

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E.

Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21.

PMID:
29221762
33.

[Nomograms in routine clinical practice: Methodology, interest and limitations].

Filleron T, Chaltiel L, Jouve E, Cabarrou B, Gilhodes J, Lusque A, Mery E, Dalenc F, Martinez A.

Bull Cancer. 2018 Jan;105(1):15-24. doi: 10.1016/j.bulcan.2017.10.024. Epub 2017 Dec 6. French.

PMID:
29221620
34.

Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.

Martinez A, Filleron T, Rouanet P, Méeus P, Lambaudie E, Classe JM, Foucher F, Narducci F, Gouy S, Guyon F, Marchal F, Jouve E, Colombo PE, Mourregot A, Rivoire M, Chopin N, Houvenaeghel G, Jaffre I, Leveque J, Lavoue V, Leblanc E, Morice P, Stoeckle E, Verheaghe JL, Querleu D, Ferron G.

Ann Surg Oncol. 2018 Feb;25(2):535-541. doi: 10.1245/s10434-017-6120-z. Epub 2017 Nov 20.

PMID:
29159738
35.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

36.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.

Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, Serhan N, Soules R, Ségala G, Mougel A, Noguer E, Mhamdi L, Bacquié E, Iuliano L, Zerbinati C, Lacroix-Triki M, Chaltiel L, Filleron T, Cavaillès V, Al Saati T, Rochaix P, Duprez-Paumier R, Franchet C, Ligat L, Lopez F, Record M, Poirot M, Silvente-Poirot S.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9346-E9355. doi: 10.1073/pnas.1707965114. Epub 2017 Oct 12.

37.

Comparison of variable selection methods for high-dimensional survival data with competing events.

Gilhodes J, Zemmour C, Ajana S, Martinez A, Delord JP, Leconte E, Boher JM, Filleron T.

Comput Biol Med. 2017 Dec 1;91:159-167. doi: 10.1016/j.compbiomed.2017.10.021. Epub 2017 Oct 20.

PMID:
29078093
38.

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial.

Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F.

Oncoimmunology. 2017 Aug 24;6(9):e1331193. doi: 10.1080/2162402X.2017.1331193. eCollection 2017.

39.

Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions.

Le Guellec S, Macagno N, Velasco V, Lamant L, Lae M, Filleron T, Malissen N, Cassagnau E, Terrier P, Chevreau C, Ranchere-Vince D, Coindre JM.

Mod Pathol. 2017 Dec;30(12):1677-1687. doi: 10.1038/modpathol.2017.91. Epub 2017 Jul 28.

40.

Cell-assisted lipotransfer: Friend or foe in fat grafting? Systematic review and meta-analysis.

Laloze J, Varin A, Gilhodes J, Bertheuil N, Grolleau JL, Brie J, Usseglio J, Sensebe L, Filleron T, Chaput B.

J Tissue Eng Regen Med. 2018 Feb;12(2):e1237-e1250. doi: 10.1002/term.2524. Epub 2017 Dec 7. Review.

PMID:
28719946
41.

Impact of surgery on survival in stage IV breast cancer.

Filleron T, Pons E, Lusque A, Dalenc F.

Breast J. 2017 Nov;23(6):774. doi: 10.1111/tbj.12822. Epub 2017 May 15. No abstract available.

PMID:
28503823
42.

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.

Cabarrou B, Mourey L, Dalenc F, Balardy L, Kanoun D, Roché H, Boher JM, Rougé-Bugat ME, Filleron T.

Breast Cancer Res Treat. 2017 Aug;164(3):505-513. doi: 10.1007/s10549-017-4278-5. Epub 2017 May 9. Review.

PMID:
28488143
43.

Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, Parrens M, Vergier B, Copie-Bergman C, Fabiani B, Traverse-Glehen A, Brousse N, Copin MC, Tas P, Petrella T, Rousselet MC, Brière J, Charlotte F, Chassagne-Clement C, Rousset T, Xerri L, Moreau A, Martin A, Damotte D, Dartigues P, Soubeyran I, Peoch M, Dechelotte P, Michiels JF, de Mascarel A, Berger F, Bossard C, Arbion F, Quintin-Roué I, Picquenot JM, Patey M, Fabre B, Sevestre H, Le Naoures C, Chenard-Neu MP, Bastien C, Thiebault S, Martin L, Delage M, Filleron T, Salles G, Molina TJ, Delsol G, Brousset P, Gaulard P.

J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.

PMID:
28459613
44.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

45.

External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.

Genre L, Roché H, Varela L, Kanoun D, Ouali M, Filleron T, Dalenc F.

Eur J Cancer. 2017 Feb;72:200-209. doi: 10.1016/j.ejca.2016.10.019. Epub 2016 Dec 30.

PMID:
28042991
46.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, Massard C, Lévy C, Arnedos M, Lacroix-Triki M, Garrabey J, Boursin Y, Deloger M, Fu Y, Commo F, Scott V, Lacroix L, Dieci MV, Kamal M, Diéras V, Gonçalves A, Ferrerro JM, Romieu G, Vanlemmens L, Mouret Reynier MA, Théry JC, Le Du F, Guiu S, Dalenc F, Clapisson G, Bonnefoi H, Jimenez M, Le Tourneau C, André F.

PLoS Med. 2016 Dec 27;13(12):e1002201. doi: 10.1371/journal.pmed.1002201. eCollection 2016 Dec.

47.

The AF-1-deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumors.

Chantalat E, Boudou F, Laurell H, Palierne G, Houtman R, Melchers D, Rochaix P, Filleron T, Stella A, Burlet-Schiltz O, Brouchet A, Flouriot G, Métivier R, Arnal JF, Fontaine C, Lenfant F.

Breast Cancer Res. 2016 Dec 7;18(1):123.

48.

[Subgroup analysis and forest plots: Limitations and interests].

Filleron T, Gilhodes J, Delord JP, Cabarrou B.

Bull Cancer. 2017 Jan;104(1):92-100. doi: 10.1016/j.bulcan.2016.09.023. Epub 2016 Nov 4. Review. French.

PMID:
27823809
49.

Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.

Boher JM, Filleron T, Giorgi R, Kramar A, Cook RJ.

Stat Med. 2017 Jan 30;36(2):362-377. doi: 10.1002/sim.7153. Epub 2016 Oct 28.

PMID:
27790725
50.

Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

Filleron T, Kouokam W, Gilhodes J, Duhamel A, Penel N, Joly F, Tresch-Bruneel E, Kramar A, Houédé N.

Ann Oncol. 2016 Nov;27(11):1981-1987. Epub 2016 Aug 8. Review.

PMID:
27502711

Supplemental Content

Loading ...
Support Center